EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET FORECAST 2017-2025
KEY FINDINGS
The Europe botanical and plant derivative drug market is predicted to be worth $9217 million by the end of 2025. The market is expected to grow at a CAGR of 2.81%, over the forecast period of 2017-2025.
MARKET INSIGHTS
Increasing demand for traditional medicines, their growing applications in diseases and the increasing number of approvals from the FDA are chiefly responsible for driving the market growth. The rising prevalence of asthma is likely to augment the demand for botanical drugs in the European market. The market is segmented on the basis of products, therapeutic applications, and types. The various types of botanical and plant derivative drugs include glycosides, steroids, terpenes, and phenols. In order to develop botanical drugs in Europe, the manufacturer has to file an Investigational New Drug application (IND), and the drug has to undergo a number of clinical trials before it is approved to be sold in the market.
COMPETITIVE INSIGHTS
Bristol-Myers Squibb, Novartis International Ag, Glenmark Pharmaceuticals Ltd, Pfizer, GlaxoSmithKline, Medigene, Abbott, Eli Lilly And Company, Bayer Healthcare, Tasly Pharmaceuticals Inc, and Piramal Phytocare Ltd are some of the eminent companies operating in this market.
The Europe botanical and plant derivative drug market is predicted to be worth $9217 million by the end of 2025. The market is expected to grow at a CAGR of 2.81%, over the forecast period of 2017-2025.
MARKET INSIGHTS
Increasing demand for traditional medicines, their growing applications in diseases and the increasing number of approvals from the FDA are chiefly responsible for driving the market growth. The rising prevalence of asthma is likely to augment the demand for botanical drugs in the European market. The market is segmented on the basis of products, therapeutic applications, and types. The various types of botanical and plant derivative drugs include glycosides, steroids, terpenes, and phenols. In order to develop botanical drugs in Europe, the manufacturer has to file an Investigational New Drug application (IND), and the drug has to undergo a number of clinical trials before it is approved to be sold in the market.
COMPETITIVE INSIGHTS
Bristol-Myers Squibb, Novartis International Ag, Glenmark Pharmaceuticals Ltd, Pfizer, GlaxoSmithKline, Medigene, Abbott, Eli Lilly And Company, Bayer Healthcare, Tasly Pharmaceuticals Inc, and Piramal Phytocare Ltd are some of the eminent companies operating in this market.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. GLYCOSIDES IS QUICKLY RISING MARKET IN TERMS OF TYPES
3.2.2. ONCOLOGY HOLDS THE LARGEST MARKET SHARE IN TERMS OF THERAPEUTIC APPLICATION
3.2.3. HERBAL/TRADITIONAL TOPICAL ANALGESICS PRODUCT IS GROWING RAPIDLY
4. MARKET DYNAMICS
4.1. DRIVERS
4.1.1. GROWING APPLICATIONS IN DISEASES
4.1.2. GROWING FDA APPROVALS
4.1.3. TECHNOLOGICAL DEVELOPMENT IN THE MANUFACTURING PROCESS
4.1.4. RISING DEMAND FOR TRADITIONAL MEDICINES
4.1.5. GROWING FOCUS TOWARDS NATURAL SOURCE MEDICINES
4.2. RESTRAINTS
4.2.1. STRINGENT REGULATIONS REGARDING THE USE AND APPROVAL OF BOTANICAL DRUGS
4.2.2. LIMITED ADOPTION OF BOTANICAL AND PLANT DERIVATIVE DRUGS
4.3. OPPORTUNITIES
4.3.1. RISING FDA APPROVALS FOR BOTANICAL DRUGS
4.3.2. ESCALATING USAGE OF BOTANICAL DRUGS
4.4. CHALLENGES
4.4.1. PRESENCE OF SUBSTITUTES FOR BOTANICAL & PLANT DERIVATIVE DRUG
4.4.2. TOXICITY RELATED ISSUES AND SAFETY CONCERNS
5. MARKET SEGMENTATION
5.1. MARKET BY TYPES 2017-2025
5.1.1. TERPENES
5.1.2. STEROIDS
5.1.3. GLYCOSIDES
5.1.4. PHENOLS
5.1.5. OTHER TYPES
5.2. MARKET BY THERAPEUTIC APPLICATIONS 2017-2025
5.2.1. ONCOLOGY
5.2.2. DERMATOLOGY
5.2.3. CNS DISORDERS
5.2.4. HORMONE DISEASES
5.2.5. OTHER THERAPEUTIC APPLICATIONS
5.3. MARKET BY PRODUCTS 2017-2025
5.3.1. HERBAL/TRADITIONAL TOPICAL ANALGESICS
5.3.2. HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES
5.3.3. HERBAL/TRADITIONAL DIGESTIVE REMEDIES
5.3.4. HERBAL/TRADITIONAL DERMATOLOGICAL
5.3.5. HERBAL/TRADITIONAL PEDIATRIC DIETARY SUPPLEMENTS
5.3.6. HERBAL/TRADITIONAL DIETARY SUPPLEMENTS
5.3.7. HERBAL/TRADITIONAL TONICS
6. KEY ANALYTICS
6.1. MANUFACTURING PROCESS
6.2. VALUE CHAIN ANALYSIS
6.3. LEGAL, POLICY AND REGULATORY FRAMEWORK
6.4. PORTER’S FIVE FORCES ANALYSIS
6.4.1. THREAT OF NEW ENTRANTS
6.4.2. THREATS OF SUBSTITUTE PRODUCT
6.4.3. BARGAINING POWER OF BUYER
6.4.4. BARGAINING POWER OF SUPPLIER
6.4.5. INTENSITY OF COMPETITIVE RIVALRY
6.5. KEY BUYING CRITERIA
7. GEOGRAPHIC ANALYSIS
7.1. EUROPE
7.1.1. UNITED KINGDOM
7.1.2. FRANCE
7.1.3. GERMANY
7.1.4. SPAIN
7.1.5. ITALY
7.1.6. REST OF EUROPE
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIES
8.1.1. MERGER & ACQUISITION
8.1.2. PARTNERSHIP & COLLABORATION
8.1.3. EXPANSION & INVESTMENT
8.2. MARKET SHARE ANALYSIS
8.3. KEY COMPANIES ANALYSIS
9. COMPANY PROFILE
9.1. ABBOTT LABORATORIES
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC INITIATIVES
9.1.4. SCOT ANALYSIS
9.2. BAYER HEALTHCARE LLC
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. SCOT ANALYSIS
9.3. BIONOVA
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.4. BRISTOL-MYERS SQUIBB
9.4.1. OVERVIEW
9.4.2. STRATEGIC INITIATIVE
9.4.3. SCOT ANALYSIS
9.5. CURA PHARM
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.6. ELI LILLY AND COMPANY
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. GLAXOSMITHKLINE
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC INITIATIVES
9.7.4. SCOT ANALYSIS
9.8. GLENMARK PHARMACEUTICALS LTD.
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. STRATEGIC INITIATIVE
9.8.4. SCOT ANALYSIS
9.9. LUPIN LTD
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. STRATEGIC INITIATIVE
9.9.4. SCOT ANALYSIS
9.10. MEDIGENE
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC INITIATIVES
9.10.4. SCOT ANALYSIS
9.11. NOVARTIS INTERNATIONAL AG
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. STRATEGIC INITIATIVES
9.11.4. SCOT ANALYSIS
9.12. PFIZER
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. STRATEGIC INITIATIVE
9.12.4. SCOT ANALYSIS
9.13. PIRAMAL PHYTOCARE LTD
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. STRATEGIC INITIATIVE
9.13.4. SCOT ANALYSIS
9.14. RANBAXY LABORATORIES LTD (ACQUIRED BY SUN PHARMACEUTICALS LTD)
9.14.1. OVERVIEW
9.14.2. PRODUCTION PORTFOLIO
9.14.3. STRATEGIC INITIATIVE-
9.14.4. SCOT ANALYSIS
9.15. TASLY PHARMACEUTICALS INC.
9.15.1. OVERVIEW
9.15.2. PRODUCTION PORTFOLIO
9.15.3. SCOT ANALYSIS
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. GLYCOSIDES IS QUICKLY RISING MARKET IN TERMS OF TYPES
3.2.2. ONCOLOGY HOLDS THE LARGEST MARKET SHARE IN TERMS OF THERAPEUTIC APPLICATION
3.2.3. HERBAL/TRADITIONAL TOPICAL ANALGESICS PRODUCT IS GROWING RAPIDLY
4. MARKET DYNAMICS
4.1. DRIVERS
4.1.1. GROWING APPLICATIONS IN DISEASES
4.1.2. GROWING FDA APPROVALS
4.1.3. TECHNOLOGICAL DEVELOPMENT IN THE MANUFACTURING PROCESS
4.1.4. RISING DEMAND FOR TRADITIONAL MEDICINES
4.1.5. GROWING FOCUS TOWARDS NATURAL SOURCE MEDICINES
4.2. RESTRAINTS
4.2.1. STRINGENT REGULATIONS REGARDING THE USE AND APPROVAL OF BOTANICAL DRUGS
4.2.2. LIMITED ADOPTION OF BOTANICAL AND PLANT DERIVATIVE DRUGS
4.3. OPPORTUNITIES
4.3.1. RISING FDA APPROVALS FOR BOTANICAL DRUGS
4.3.2. ESCALATING USAGE OF BOTANICAL DRUGS
4.4. CHALLENGES
4.4.1. PRESENCE OF SUBSTITUTES FOR BOTANICAL & PLANT DERIVATIVE DRUG
4.4.2. TOXICITY RELATED ISSUES AND SAFETY CONCERNS
5. MARKET SEGMENTATION
5.1. MARKET BY TYPES 2017-2025
5.1.1. TERPENES
5.1.2. STEROIDS
5.1.3. GLYCOSIDES
5.1.4. PHENOLS
5.1.5. OTHER TYPES
5.2. MARKET BY THERAPEUTIC APPLICATIONS 2017-2025
5.2.1. ONCOLOGY
5.2.2. DERMATOLOGY
5.2.3. CNS DISORDERS
5.2.4. HORMONE DISEASES
5.2.5. OTHER THERAPEUTIC APPLICATIONS
5.3. MARKET BY PRODUCTS 2017-2025
5.3.1. HERBAL/TRADITIONAL TOPICAL ANALGESICS
5.3.2. HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES
5.3.3. HERBAL/TRADITIONAL DIGESTIVE REMEDIES
5.3.4. HERBAL/TRADITIONAL DERMATOLOGICAL
5.3.5. HERBAL/TRADITIONAL PEDIATRIC DIETARY SUPPLEMENTS
5.3.6. HERBAL/TRADITIONAL DIETARY SUPPLEMENTS
5.3.7. HERBAL/TRADITIONAL TONICS
6. KEY ANALYTICS
6.1. MANUFACTURING PROCESS
6.2. VALUE CHAIN ANALYSIS
6.3. LEGAL, POLICY AND REGULATORY FRAMEWORK
6.4. PORTER’S FIVE FORCES ANALYSIS
6.4.1. THREAT OF NEW ENTRANTS
6.4.2. THREATS OF SUBSTITUTE PRODUCT
6.4.3. BARGAINING POWER OF BUYER
6.4.4. BARGAINING POWER OF SUPPLIER
6.4.5. INTENSITY OF COMPETITIVE RIVALRY
6.5. KEY BUYING CRITERIA
7. GEOGRAPHIC ANALYSIS
7.1. EUROPE
7.1.1. UNITED KINGDOM
7.1.2. FRANCE
7.1.3. GERMANY
7.1.4. SPAIN
7.1.5. ITALY
7.1.6. REST OF EUROPE
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIES
8.1.1. MERGER & ACQUISITION
8.1.2. PARTNERSHIP & COLLABORATION
8.1.3. EXPANSION & INVESTMENT
8.2. MARKET SHARE ANALYSIS
8.3. KEY COMPANIES ANALYSIS
9. COMPANY PROFILE
9.1. ABBOTT LABORATORIES
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC INITIATIVES
9.1.4. SCOT ANALYSIS
9.2. BAYER HEALTHCARE LLC
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. SCOT ANALYSIS
9.3. BIONOVA
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.4. BRISTOL-MYERS SQUIBB
9.4.1. OVERVIEW
9.4.2. STRATEGIC INITIATIVE
9.4.3. SCOT ANALYSIS
9.5. CURA PHARM
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.6. ELI LILLY AND COMPANY
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. GLAXOSMITHKLINE
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC INITIATIVES
9.7.4. SCOT ANALYSIS
9.8. GLENMARK PHARMACEUTICALS LTD.
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. STRATEGIC INITIATIVE
9.8.4. SCOT ANALYSIS
9.9. LUPIN LTD
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. STRATEGIC INITIATIVE
9.9.4. SCOT ANALYSIS
9.10. MEDIGENE
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC INITIATIVES
9.10.4. SCOT ANALYSIS
9.11. NOVARTIS INTERNATIONAL AG
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. STRATEGIC INITIATIVES
9.11.4. SCOT ANALYSIS
9.12. PFIZER
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. STRATEGIC INITIATIVE
9.12.4. SCOT ANALYSIS
9.13. PIRAMAL PHYTOCARE LTD
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. STRATEGIC INITIATIVE
9.13.4. SCOT ANALYSIS
9.14. RANBAXY LABORATORIES LTD (ACQUIRED BY SUN PHARMACEUTICALS LTD)
9.14.1. OVERVIEW
9.14.2. PRODUCTION PORTFOLIO
9.14.3. STRATEGIC INITIATIVE-
9.14.4. SCOT ANALYSIS
9.15. TASLY PHARMACEUTICALS INC.
9.15.1. OVERVIEW
9.15.2. PRODUCTION PORTFOLIO
9.15.3. SCOT ANALYSIS
LIST OF TABLES
Table 1 EUROPE BOTANICAL & PLANT DERIVATIVE DRUG MARKET, 2017-2025 ($ MILLION)
Table 2 EUROPE BOTANICAL & PLANT DERIVATIVE DRUG MARKET, BY TYPES 2017-2025 ($ MILLION)
Table 3 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN TERPENES, 2017-2025 ($ MILLION)
Table 4 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN STEROIDS 2017-2025 ($ MILLION)
Table 5 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES, BY GEOGRAPHY 2017-2025 ($ MILLION)
Table 6 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN PHENOLS, 2017-2025 ($ MILLION)
Table 7 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER TYPES 2017-2025 ($ MILLION)
Table 8 EUROPE BOTANICAL & PLANT DERIVATIVE DRUG MARKET BY THERAPEUTIC APPLICATIONS 2017-2025 ($ MILLION)
Table 9 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN ONCOLOGY, 2017-2025 ($ MILLION)
Table 10 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN DERMATOLOGY, 2017-2025 ($ MILLION)
Table 11 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN CNS DISORDERS, 2017-2025 ($ MILLION)
Table 12 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHERS THERAPEUTIC APPLICATIONS 2017-2025 ($ MILLION)
Table 13 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET, BY PRODUCT 2017-2025 ($ MILLION)
Table 14 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TOPICAL ANALGESICS, 2017-2025 ($ MILLION)
Table 15 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES, 2017-2025 ($ MILLION)
Table 16 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIGESTIVE REMEDIES, 2017-2025 ($ MILLION)
Table 17 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DERMATOLOGICALS, 2017-2025 ($ MILLION)
Table 18 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL PAEDIATRIC DIETARY SUPPLEMENTS, 2017-2025 ($ MILLION)
Table 19 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIETARY SUPPLEMENTS, 2017-2025 ($ MILLION)
Table 20 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TONICS, 2017-2025 ($ MILLION)
Table 21 EUROPE BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Table 1 EUROPE BOTANICAL & PLANT DERIVATIVE DRUG MARKET, 2017-2025 ($ MILLION)
Table 2 EUROPE BOTANICAL & PLANT DERIVATIVE DRUG MARKET, BY TYPES 2017-2025 ($ MILLION)
Table 3 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN TERPENES, 2017-2025 ($ MILLION)
Table 4 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN STEROIDS 2017-2025 ($ MILLION)
Table 5 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES, BY GEOGRAPHY 2017-2025 ($ MILLION)
Table 6 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN PHENOLS, 2017-2025 ($ MILLION)
Table 7 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER TYPES 2017-2025 ($ MILLION)
Table 8 EUROPE BOTANICAL & PLANT DERIVATIVE DRUG MARKET BY THERAPEUTIC APPLICATIONS 2017-2025 ($ MILLION)
Table 9 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN ONCOLOGY, 2017-2025 ($ MILLION)
Table 10 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN DERMATOLOGY, 2017-2025 ($ MILLION)
Table 11 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN CNS DISORDERS, 2017-2025 ($ MILLION)
Table 12 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHERS THERAPEUTIC APPLICATIONS 2017-2025 ($ MILLION)
Table 13 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET, BY PRODUCT 2017-2025 ($ MILLION)
Table 14 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TOPICAL ANALGESICS, 2017-2025 ($ MILLION)
Table 15 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES, 2017-2025 ($ MILLION)
Table 16 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIGESTIVE REMEDIES, 2017-2025 ($ MILLION)
Table 17 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DERMATOLOGICALS, 2017-2025 ($ MILLION)
Table 18 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL PAEDIATRIC DIETARY SUPPLEMENTS, 2017-2025 ($ MILLION)
Table 19 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIETARY SUPPLEMENTS, 2017-2025 ($ MILLION)
Table 20 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TONICS, 2017-2025 ($ MILLION)
Table 21 EUROPE BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
LIST OF FIGURES
Figure 1 EUROPE BOTANICAL & PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES 2017-2025 ($ MILLION)
Figure 2 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN TERPENES 2017-2025 ($ MILLION)
Figure 3 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN STEROIDS 2017-2025 ($ MILLION)
Figure 4 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES 2017-2025 ($ MILLION)
Figure 5 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN PHENOLS 2017-2025 ($ MILLION)
Figure 6 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER TYPES 2017-2025 ($ MILLION)
Figure 7 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN ONCOLOGY 2017-2025 ($ MILLION)
Figure 8 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN DERMATOLOGY 2017-2025 ($ MILLION)
Figure 9 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN CNS DISORDERS 2017-2025 ($ MILLION)
Figure 10 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HORMONE DISEASE 2017-2025 ($ MILLION)
Figure 11 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HORMONE DISEASE, 2017-2025 ($ MILLION)
Figure 12 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHERS THERAPEUTIC APPLICATIONS 2017-2025 ($ MILLION)
Figure 13 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TOPICAL ANALGESICS 2017-2025 ($ MILLION)
Figure 14 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES 2017-2025 ($ MILLION)
Figure 15 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIGESTIVE REMEDIES 2017-2025 ($ MILLION)
Figure 16 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DERMATOLOGICALS 2017-2025 ($ MILLION)
Figure 17 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL PAEDIATRIC DIETARY SUPPLEMENTS 2017-2025 ($ MILLION)
Figure 18 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIETARY SUPPLEMENTS 2017-2025 ($ MILLION)
Figure 19 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TONICS 2017-2025 ($ MILLION)
Figure 20 EVOLUTION OF BOTANICAL AND PLANT DERIVATIVE DRUGS
Figure 21 UK BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 22 FRANCE BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 23 GERMANY BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 24 SPAIN BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 25 ITALY BOTANICAL PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 26 REST OF EUROPE BOTANICAL &PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 1 EUROPE BOTANICAL & PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES 2017-2025 ($ MILLION)
Figure 2 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN TERPENES 2017-2025 ($ MILLION)
Figure 3 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN STEROIDS 2017-2025 ($ MILLION)
Figure 4 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES 2017-2025 ($ MILLION)
Figure 5 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN PHENOLS 2017-2025 ($ MILLION)
Figure 6 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER TYPES 2017-2025 ($ MILLION)
Figure 7 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN ONCOLOGY 2017-2025 ($ MILLION)
Figure 8 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN DERMATOLOGY 2017-2025 ($ MILLION)
Figure 9 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN CNS DISORDERS 2017-2025 ($ MILLION)
Figure 10 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HORMONE DISEASE 2017-2025 ($ MILLION)
Figure 11 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HORMONE DISEASE, 2017-2025 ($ MILLION)
Figure 12 EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHERS THERAPEUTIC APPLICATIONS 2017-2025 ($ MILLION)
Figure 13 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TOPICAL ANALGESICS 2017-2025 ($ MILLION)
Figure 14 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES 2017-2025 ($ MILLION)
Figure 15 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIGESTIVE REMEDIES 2017-2025 ($ MILLION)
Figure 16 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DERMATOLOGICALS 2017-2025 ($ MILLION)
Figure 17 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL PAEDIATRIC DIETARY SUPPLEMENTS 2017-2025 ($ MILLION)
Figure 18 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIETARY SUPPLEMENTS 2017-2025 ($ MILLION)
Figure 19 EUROPE BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TONICS 2017-2025 ($ MILLION)
Figure 20 EVOLUTION OF BOTANICAL AND PLANT DERIVATIVE DRUGS
Figure 21 UK BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 22 FRANCE BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 23 GERMANY BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 24 SPAIN BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 25 ITALY BOTANICAL PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 26 REST OF EUROPE BOTANICAL &PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
